2018 Idiopathic Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Idiopathic Hypertension Market

  • ID: 4577806
  • Report
  • 70 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Bayer AG
  • Hypogen, Inc.
  • Merck KGaA
  • Novartis International AG
  • Quantum Genomics SA
  • MORE
2018 Idiopathic Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Idiopathic Hypertension Market is a comprehensive report on idiopathic hypertension market.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Idiopathic Hypertension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Idiopathic Hypertension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Idiopathic Hypertension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actelion Ltd
  • Bayer AG
  • Hypogen, Inc.
  • Merck KGaA
  • Novartis International AG
  • Quantum Genomics SA
  • MORE
1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Idiopathic Hypertension Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Idiopathic Hypertension Pipeline Snapshot
2.3 Idiopathic Hypertension Pipeline by Phase
2.4 Idiopathic Hypertension Pipeline by Company
2.5 Idiopathic Hypertension Pipeline by Mechanism of Action

3 Idiopathic Hypertension- Company Wise Pipeline Analysis
Actelion Ltd
Bayer AG
Beijing CoSci Med-Tech Co.,Ltd
Boryung Pharmaceutical Co., Ltd
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
HanAll Biopharma Co., Ltd.
Hypogen, Inc.
Il Dong Pharmaceutical Co Ltd
Merck KGaA
Novartis International AG
Quantum Genomics SA
RMJ Holdings, LLC
Shin Poong Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited
Theracos, Inc.
Yuhan Co, Ltd.

4 Idiopathic Hypertension R&D Pipeline Snapshots
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 Recent Developments in Idiopathic Hypertension Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

Figures
Figure 1: Idiopathic Hypertension Pipeline by Phase, H2- 2018
Figure 2: Idiopathic Hypertension Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Idiopathic Hypertension Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

Tables
Idiopathic Hypertension Pipeline by Phase, H2- 2018
Idiopathic Hypertension Pipeline by Companies, H2- 2018
Idiopathic Hypertension Pipeline by Mechanism of Action, H2- 2018
Table 1: Actelion Ltd Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 2: Bayer AG Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 4: Boryung Pharmaceutical Co., Ltd Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 5: Chong Kun Dang Pharmaceutical Corp. Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 6: Daiichi Sankyo Company, Limited Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 7: HanAll Biopharma Co., Ltd. Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 8: Hypogen, Inc. Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 9: Il Dong Pharmaceutical Co Ltd Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 10: Merck KGaA Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 11: Novartis International AG Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 12: Quantum Genomics SA Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 13: RMJ Holdings, LLC Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 14: Shin Poong Pharmaceutical Co Ltd Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 15: Takeda Pharmaceutical Company Limited Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 16: Theracos, Inc. Idiopathic Hypertension Pipeline Drugs, H2- 2018
Table 17: Yuhan Co, Ltd. Idiopathic Hypertension Pipeline Drugs, H2- 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Actelion Ltd
  • Bayer AG
  • Beijing CoSci Med-Tech Co.,Ltd
  • Boryung Pharmaceutical Co., Ltd
  • Chong Kun Dang Pharmaceutical Corp.
  • Daiichi Sankyo Company, Limited
  • HanAll Biopharma Co., Ltd.
  • Hypogen, Inc.
  • Il Dong Pharmaceutical Co Ltd
  • Merck KGaA
  • Novartis International AG
  • Quantum Genomics SA
  • RMJ Holdings, LLC
  • Shin Poong Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Company Limited
  • Theracos, Inc.
  • Yuhan Co, Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll